Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance
<b>Background:</b> Olaparib and niraparib are poly (ADP-ribose) polymerase inhibitors (PARPi) used primarily for the treatment of ovarian cancer. While both drugs have demonstrated efficacy in clinical trials, their safety profiles, particularly in real-world clinical settings, remain to...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/4/528 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850179978731192320 |
|---|---|
| author | Desirèe Speranza Fausto Omero Vincenzo Cianci Mariapia Marafioti Carla Infurna Patrizia Carroccio Edoardo Spina Maria Antonietta Barbieri Emanuela Esposito Nicola Silvestris Mariacarmela Santarpia |
| author_facet | Desirèe Speranza Fausto Omero Vincenzo Cianci Mariapia Marafioti Carla Infurna Patrizia Carroccio Edoardo Spina Maria Antonietta Barbieri Emanuela Esposito Nicola Silvestris Mariacarmela Santarpia |
| author_sort | Desirèe Speranza |
| collection | DOAJ |
| description | <b>Background:</b> Olaparib and niraparib are poly (ADP-ribose) polymerase inhibitors (PARPi) used primarily for the treatment of ovarian cancer. While both drugs have demonstrated efficacy in clinical trials, their safety profiles, particularly in real-world clinical settings, remain to be fully elucidated. <b>Objectives:</b> This study aimed to (i) characterize the adverse drug reactions (ADRs) associated with olaparib and niraparib as reported in the EudraVigilance database, (ii) compare the frequency of the ADRs occurring during treatment with the two drugs, and (iii) compare post-marketing safety data with those from clinical trials. <b>Methods:</b> A retrospective analysis was performed using data from the EudraVigilance database (2017–2024), focusing on individual case safety reports (ICSRs) related to olaparib and niraparib. Descriptive statistics and disproportionality analysis were performed to compare the frequency and severity of reported ADRs. <b>Results:</b> Both olaparib and niraparib had common ADRs including nausea, vomiting, anemia, thrombocytopenia, and fatigue. However, olaparib was associated with a higher risk of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and interstitial lung disease, while niraparib had a higher incidence of gastrointestinal events and thrombocytopenia. Our analysis demonstrates that some specific ADRs, including peripheral neuropathy with niraparib, were reported at higher frequencies compared to clinical trials. The incidence of serious ADRs, including hospitalizations and life-threatening events, was higher with niraparib than with olaparib. <b>Conclusions:</b> This study highlights significant differences in the safety profiles of olaparib and niraparib, with implications for clinical decision-making. Continuous monitoring and personalized management of ADRs are essential to optimize patient outcomes. |
| format | Article |
| id | doaj-art-abf5aa7142494a4d84c2cb1b04439a07 |
| institution | OA Journals |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-abf5aa7142494a4d84c2cb1b04439a072025-08-20T02:18:20ZengMDPI AGPharmaceuticals1424-82472025-04-0118452810.3390/ph18040528Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilanceDesirèe Speranza0Fausto Omero1Vincenzo Cianci2Mariapia Marafioti3Carla Infurna4Patrizia Carroccio5Edoardo Spina6Maria Antonietta Barbieri7Emanuela Esposito8Nicola Silvestris9Mariacarmela Santarpia10Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, ItalyDepartment of Human Pathology “G. Barresi”, School of Specialization in Medical Oncology, University of Messina, 98125 Messina, ItalyDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, Section of Legal Medicine, University of Messina, 98125 Messina, ItalyDepartment of Human Pathology “G. Barresi”, School of Specialization in Medical Oncology, University of Messina, 98125 Messina, ItalyDepartment of Human Pathology “G. Barresi”, School of Specialization in Medical Oncology, University of Messina, 98125 Messina, ItalyDepartment of Human Pathology “G. Barresi”, School of Specialization in Medical Oncology, University of Messina, 98125 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98122 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98122 Messina, ItalyDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, ItalyMedical Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, ItalyMedical Oncology Unit, Department of Human Pathology “G. Barresi”, University of Messina, 98122 Messina, Italy<b>Background:</b> Olaparib and niraparib are poly (ADP-ribose) polymerase inhibitors (PARPi) used primarily for the treatment of ovarian cancer. While both drugs have demonstrated efficacy in clinical trials, their safety profiles, particularly in real-world clinical settings, remain to be fully elucidated. <b>Objectives:</b> This study aimed to (i) characterize the adverse drug reactions (ADRs) associated with olaparib and niraparib as reported in the EudraVigilance database, (ii) compare the frequency of the ADRs occurring during treatment with the two drugs, and (iii) compare post-marketing safety data with those from clinical trials. <b>Methods:</b> A retrospective analysis was performed using data from the EudraVigilance database (2017–2024), focusing on individual case safety reports (ICSRs) related to olaparib and niraparib. Descriptive statistics and disproportionality analysis were performed to compare the frequency and severity of reported ADRs. <b>Results:</b> Both olaparib and niraparib had common ADRs including nausea, vomiting, anemia, thrombocytopenia, and fatigue. However, olaparib was associated with a higher risk of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and interstitial lung disease, while niraparib had a higher incidence of gastrointestinal events and thrombocytopenia. Our analysis demonstrates that some specific ADRs, including peripheral neuropathy with niraparib, were reported at higher frequencies compared to clinical trials. The incidence of serious ADRs, including hospitalizations and life-threatening events, was higher with niraparib than with olaparib. <b>Conclusions:</b> This study highlights significant differences in the safety profiles of olaparib and niraparib, with implications for clinical decision-making. Continuous monitoring and personalized management of ADRs are essential to optimize patient outcomes.https://www.mdpi.com/1424-8247/18/4/528olaparibniraparibEudraVigilancepharmacovigilancePARP inhibitorsreal-world data |
| spellingShingle | Desirèe Speranza Fausto Omero Vincenzo Cianci Mariapia Marafioti Carla Infurna Patrizia Carroccio Edoardo Spina Maria Antonietta Barbieri Emanuela Esposito Nicola Silvestris Mariacarmela Santarpia Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance Pharmaceuticals olaparib niraparib EudraVigilance pharmacovigilance PARP inhibitors real-world data |
| title | Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance |
| title_full | Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance |
| title_fullStr | Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance |
| title_full_unstemmed | Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance |
| title_short | Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance |
| title_sort | comparison study of the safety profile of olaparib versus niraparib analysis of real world data from eudravigilance |
| topic | olaparib niraparib EudraVigilance pharmacovigilance PARP inhibitors real-world data |
| url | https://www.mdpi.com/1424-8247/18/4/528 |
| work_keys_str_mv | AT desireesperanza comparisonstudyofthesafetyprofileofolaparibversusniraparibanalysisofrealworlddatafromeudravigilance AT faustoomero comparisonstudyofthesafetyprofileofolaparibversusniraparibanalysisofrealworlddatafromeudravigilance AT vincenzocianci comparisonstudyofthesafetyprofileofolaparibversusniraparibanalysisofrealworlddatafromeudravigilance AT mariapiamarafioti comparisonstudyofthesafetyprofileofolaparibversusniraparibanalysisofrealworlddatafromeudravigilance AT carlainfurna comparisonstudyofthesafetyprofileofolaparibversusniraparibanalysisofrealworlddatafromeudravigilance AT patriziacarroccio comparisonstudyofthesafetyprofileofolaparibversusniraparibanalysisofrealworlddatafromeudravigilance AT edoardospina comparisonstudyofthesafetyprofileofolaparibversusniraparibanalysisofrealworlddatafromeudravigilance AT mariaantoniettabarbieri comparisonstudyofthesafetyprofileofolaparibversusniraparibanalysisofrealworlddatafromeudravigilance AT emanuelaesposito comparisonstudyofthesafetyprofileofolaparibversusniraparibanalysisofrealworlddatafromeudravigilance AT nicolasilvestris comparisonstudyofthesafetyprofileofolaparibversusniraparibanalysisofrealworlddatafromeudravigilance AT mariacarmelasantarpia comparisonstudyofthesafetyprofileofolaparibversusniraparibanalysisofrealworlddatafromeudravigilance |